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A B S T R A C T
Vagus nerve stimulation (VNS) for the treatment of refractory partial epileptic seizures with or without secondary
generalisation in patients older than 12 years was approved in Europe in 1994 and in the United States in 1997. We have
studied the efficacy of VNS in patients with pharmacoresistant epilepsy hospitalized in the Neurology Department of the
University Hospital Centre Zagreb. From 1997 do 2001 we have implanted VNS in 11 patients with pharmacoresistant
epilepsy, who were magnetic resonance imaging (MRI) negative and from May 2007 to May 2009 in 11 patients with
pharmacoresistant epilepsy, 9 of them were MRI positive, and were inoperable due to localisation of the pathomorpho-
logic changes (ganglioglioma, hamartoma, various types of cortical dysplasia, porencephalic cysts), 2 were MR negative.
In the group of MRI negative patients 1 patient had complex partial seizures (CPS), 6 patients had CPS with secondary
generalisation, 2 patients had primary generalized epilepsy (PGE) including myoclonic, absence, atonic and tonic-clonic
seizures, one patient had PGE and CPS, and 3 patients had Lennox-Gastaut syndrome (LGS). In the group of MRI posi-
tive patients one patient had elementary partial seizures (EPS) and CPS, two patients had EPS and CPS with secondary
generalisation, one patient had CPS, 3 patients had CPS with secondary generalisation, and 2 patients had CPS with
secondary generalisation as well as atonic seizures. After continuous follow-up of 11 MRI negative patients during 5
years and 2 MRI negative patients during one year there was decrease in mean-seizure frequency of 51.67%. After continu-
ous follow-up of 9 MRI positive patients during 2 years there was decrease in mean-seizure frequency of 61.9 %. The most
frequent side effects were hoarseness, throat pain and cough in the »on phase« of the VNS, but they were mild and transi-
tory. We can conclude that VNS was effective mode of therapy in our group of patients with pharmacoresistant epilepsy.
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Introduction
Many patients with epilepsy suffer from persistent
seizures despite optimal antiepileptic therapy (AET).
Surgical resection, such as temporal lobectomy for me-
sial temporal sclerosis, can result in a dramatic reduction
in seizure frequency (chances of seizure-free results are
high – 70–90%), but only in selected patients1. Generally,
complication rates of epilepsy surgery are relatively low
and thought to be acceptable, with approximately 1 to 2%
permanent morbidity1,2. Chronic, intermittent vagus ner-
ve stimulation (VNS) has proven to be a safe, effective
option for patients suffering from refractory seizures
who are not candidates for surgical resection. Although
only a small minority of patients will be entirely sei-
zure-free, VNS as an adjunct to medical therapy does
appear to provide a significant amount of improvement
in the quality of life. The neurocybernetic prosthesis
(NCP) system developed by Cyberonics (Webster, TX) for
the treatment of refractory partial epileptic seizures with
or without secondary generalisation in patients aged 12
years or older was approved in Europe in 1994 and in the
United States in 19973,4.
VNS consists of a pulse generator, bipolar electrodes,
programator with software for IBM compatible comput-
ers, guide and magnetic plate for autoregulation. The
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generator is surgically placed in a pocket formed under
the skin, below the left collarbone. Bipolar electrodes are
wrapped around the left vagus nerve (middle cervical
part). The generator is set to 0mA initially followed by an
increase in the output current. Beginning parameter set-
tings of 30-Hz signal frequency, 500-ms pulse width, 30
seconds on-time, and 5 minutes off-time have been found
to be effective in double-blind, controlled studies, al-
though these parameters may vary considerably in prac-
tice (from the literature data off-time could be set from 5
to 180 minutes). In addition, a hand-held magnet can be
used by patients or caregivers to activate VNS in re-
sponse to an aura or seizure onset5–7. Cardiac arrhyth-
mias are a potential theoretical risk with VNS, for this
reason, electrodes are implanted around the left vagus
nerve only8.
Patients and Methods
We have studied the efficacy of VNS in patients with
pharmacoresistant epilepsy hospitalized in the Depart-
ment of Neurology of the University Hospital Zagreb.
From 1997 do 2001 we have implanted VNS in 11 pa-
tients with pharmacoresistant epilepsy (6M, 5F), mean
age 26.62±4.93, who were magnetic resonance imaging
(MRI) negative and fromMay 2007 to May 2009 in 11 pa-
tients with pharmacoresistant epilepsy (5M, 6F), mean
age 30.61±12.76; 9 of them were MRI positive (4M, 5 F),
mean age 26.89±8.45, and were inoperable due to local-
isation of the pathomorphologic changes (ganglioglioma,
hamartoma, various types of cortical dysplasia, poren-
cephalic cysts, see details on Table 1), 2 were MR
negative (1M, 1F), mean age 50±22.63.
From 2001 to 2007, due to financial reasons, we were
not in the possibility to perform implantations. In the
group of MRI negative patients 1 patient had complex
partial seizures (CPS), 6 patients had CPS with second-
ary generalisation, 2 patients had primary generalized
epilepsy (PGE) including myoclonic, absence, atonic and
tonic-clonic seizures, one patient had PGE and CPS, and
3 patients had Lennox-Gastaut syndrome (LGS). In the
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TABLE 1
BRAIN MRI FINDINGS IN MRI POSITIVE PATIENTS
Number of
patients
Periventricular nodular heterotopia and
hamartoma (parietal)
1
Polymicrogyria (frontal and parietal) 1
Polymicrogyria (frontal) 1
Polymicrogyria (occipital) 1
Frontoparietal ganglioglioma (precentral and
postcentral)
1
Focal cortical dysplasia (frontal) 1
Bilateral frontoparietal porencephalic cysts (af-
ter perinatal stroke)
1
Bilateral frontal cortical atrophy 1
Focal cortical dysplasia (frontal and temporal) 1
TABLE 2
MAIN CHARACTERISTICS OF PATIENTS WHO WERE CANDIDATES FOR VNS IMPLANTATION
2a. Characteristics of MRI negative patients
Seizure type Number of patients Mean disease duration (years) Mean number of AEDs
before VNS, X±SD X±SD
CPS 1 19 4
CPS+SG 6 19.34±14 4.17±0.75
PGE 2 18±7.78 3
PGE+CPS 1 22 5
Lennox-Gastaut syndrome 3 22.33±12.09 4±1
2b. Characteristics of MRI positive patients
Seizure type Number of patients Mean disease duration (years) Mean number of AEDs
before VNS, X±SD X±SD
EPS+CPS 1 33 4
EPS+CPS+SG 2 13.5±0.7 3.5±0.7
CPS 1 30 3
CPS+SG 3 22.34±12.42 4.34±0.58
CPS+SG+atonic 2 14±6.65 4
SG – secondary generalisation (periodically, i.e. grand mal seizure did not follow every partial seizure)
PGE – myoclonic + absence + atonic + tonic-clonic seizures
group of MRI positive patients one patient had elemen-
tary partial seizures (EPS) and CPS, two patients had
EPS and CPS with secondary generalisation, one patient
had CPS, 3 patients had CPS with secondary generalisa-
tion, and 2 patients had CPS with secondary generalisa-
tion as well as atonic seizures. Tables 2a and 2b in details
summarize main characteristics of patients, including
data about epilepsy classification (seizure type), mean
disease duration and mean number of failed antiepileptic
drugs (AEDs). Except one patient with asthma, there
were no other comorbidities.
We have divided patients into two groups – MRI nega-
tive and MRI positive patients, because we wanted to
compare the effectiveness of this surgical method of
treatment in relation to certain brain patomorphologic
changes.
Number of seizures was obtained retrospectively dur-
ing follow up visits, that were organized in the first year
after operation every month, and in the next years every
3 months. We calculated mean number of seizures on a
monthly basis during follow-up period.
Intensity of the stimulation
One week after implantation we began stimulation
with the lowest current (0.25 mA). The stimulation was
being increased gradually in the next months. VNS pa-
rameters were adjusted according to a clinical response
in an individual patient – we increased the intensity of
the stimulation till we achieved the satisfactory reduc-
tion in the number of seizures. The final intensity of the
stimulation in the group od MRI negative patients was
from 0.75 to 2 mA: in one patient with CPS 0.75 mA, in 6
patients with CPS with secondary generalisation from
1.5 to 2 mA, in 2 patients with PGE from 1.25 to 2 mA, in
one patient with PGE and CPS 0.75 mA, and in 3 pa-
tients with Lennox-Gastaut syndrome 2 mA. In the
group of MRI positive patients the final intensity of the
stimulation was from 0.25 to 2 mA: in one patient with
EPS and CPS 1.25 mA, in 2 patients with EPS and CPS
with secondary generalisation 0.75 and 1.50 mA, in one
patient with CPS 2 mA, in 3 patients with CPS with sec-
ondary generalisation from 0.75 to 1.75 mA, and in 2 pa-
tients with CPS with secondary generalisation as well as
atonic seizures from 1.5 to 2mA.
The duty cycle was on the basis of controlled clinical
trials set to 30-Hz signal frequency, 500-ms pulse width,
30 seconds on-time, and 5 minutes off-time. After VNS
implantation there was no reduction in the dose and
number of AEDs, patients stayed on stable AED regimen.
Statistics
The results were expressed by mean values and stan-
dard deviation. The differences between groups were
tested by Student t-test. The value of p<0.05 was consid-
ered statistically significant.
Side effects and complications of the procedure
In the group of MRI negative patients one patient
died 3 years after VNS implantation (most probably as a
consequence of suffocation after grand mal seizure), one
patient experienced transient asystole during device im-
plantation that was successfully treated with atropine (1
mg i.v.), other patients complained about transient mild
hoarseness, throat pain and cough in the »on phase« of
the VNS.
In the group of MRI positive patients one patient ex-
perienced serial EPS at the intensity of the stimulation
of 0.50 mA, this patient also experienced worsening of
asthma and had muscular pain on the place of implanted
generator and was operated again due to pulse generator
dislocation in the left pectoral region. It is important to
mention that this patient was a woman of asthenic con-
stitution. One patient experienced transitory hypoten-
sion at the intensity of stimulation of 0.50 mA, other pa-
tients complained about transient mild hoarseness, throat
pain and cough in the »on phase« of the VNS.
Results
In all our patients overall seizure control continued to
improve with time, and except the decrease in seizure
frequency seizures became shorter and less intensive.
After continuous follow-up of 11 MRI negative pa-
tients during 5 years and 2 MRI negative patients during
one year there was decrease in the mean-seizure fre-
quency of 51.67% (Table 3). Reduction in the mean sei-
zure frequency after first three months was 33.3%, after
first year 42.4%, after second year 50.7%, after third year
51.5%, and after fourth year 51.88%.
After continuous follow-up of 9 MRI positive patients
during 2 years there was decrease in the mean-seizure
frequency of 61.9% (Table 4). Reduction in the mean sei-
zure frequency after first three months was 38.4%, and
after first year 56.7%.
We have observed improvement of mood and the gen-
eral quality of life in all patients.
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TABLE 3
COMPARATION OF MONTHLY NUMBER OF SEIZURES BEFORE
AND AFTER VNS IMPLANTATION IN MRI NEGATIVE PATIENTS
(FOLLOW UP: 5 YEARS FOR 11 PATIENTS AND ONE YEAR FOR
TWO PATIENTS)
Seizure type
Monthly number
of seizures before
implantation, X±SD
Monthly number of
seizures after
implantation, X±SD
CPS 8 4
CPS+SG 12±5.22 5.83±3.71; p=0.01
PGE 18±2.83 4.5±0.71; p=0.07
PGE+CPS 30 20
Lennox-Gastaut
syndrome* 26.67±5.77 13.34±2.88; p=0.02
* One of the patients with Lennox-Gastaut syndrome was com-
pletely seizure free after VNS implantation
Discussion
It is agreed that 1% of the general population is af-
fected with epilepsy and close to 30% of epilepsy patients
are pharmacoresistant. In spite of a recent increase in
the number of new medications that are available on the
market, many patients continue to have seizures or their
seizures are controlled at the expense of intolerable side
effects. Resection epilepsy surgery is an alternative. Im-
provements in imaging resulted in an increased ability
for preoperative identification of intracerebral and po-
tentially epileptogenic lesions. High resolution MRI plays
a major role in structural and functional imaging; other
functional imaging techniques (e.g., positron emission
tomography and single-photon emission computed to-
mography) provide complementary data and, together
with corresponding electroencephalographic findings, re-
sult in a hypothesis of the epileptogenic lesion, epilep-
togenic zone, and the functional deficit zone1. However,
not every pharmacoresistant patient is a good candidate
for neurosurgical treatment. Additionally, it is only of-
fered to a small fraction of those patients due to the lack
of an adequate number of comprehensive epilepsy pro-
grams and financial support for such surgeries. In other
patients with pharmacoresistant epilepsy we can offer
vagus nerve stimulation (VNS), whose efficacy is well es-
tablished in adults and adolescents with partial epilepsy
with or without secondary generalisation. In several
small studies that included patients with LGS, 37–73% of
patients had a >50% decrease in seizures9.
Side effects in our patients – hoarseness, throat pain,
cough and dyspnea, usually occurring in association with
stimulation, coincide with the side effects formerly de-
scribed in the literature10,11. However, transitory hypo-
tension noticed in our patient was not, to our knowledge,
described in the literature as a side effect of VNS so far.
Ventricular asystole due to complete atrioventricular no-
dal block has been reported as a rare but potentially seri-
ous complication of initial intraoperative testing during
the device implantation12,13. Ventricular asystole is tran-
sient and generally of brief duration (<15 seconds),
although one case lasted 45 seconds. The mechanism is
unknown, but may be related to direct activation of the
parasympathetic pathway to the heart (the left vagus
nerve has a greater chronotropic effect on the atrioven-
tricular node, while the right vagus nerve affects mostly
the sinoatrial node) or to activation of afferent vagal
pathways via the nucleus of the tractus solitarius affect-
ing cardiovascular reflexes. Only one of our patients ex-
perienced transient asystole during device implantation.
Other common adverse events of VNS, that were not
present in our group of patients, include bleeding and in-
fection from the surgery, pharyngitis, dyspepsia, dys-
phagia, nausea, vomiting, headache, paresthesia in the
neck, and psychosis13.
Unlike chronic treatment with antiepileptic medica-
tion, the benefit of VNS therapy is maintained during
prolonged stimulation, and overall seizure control (per-
centage change from baseline and response rates) contin-
ues to improve with time. We have also observed progres-
sive decrease in seizure frequency in our group of pa-
tients with implanted VNS. Preliminary results of pilot
studies demonstrated significant reduction in the fre-
quency, intensity, and duration of seizures with chronic,
intermittent VNS14,15, which led to subsequent multi-
center, double-blinded, randomized controlled trials in
adults with medically refractory epilepsy16,17. These tri-
als demonstrated a mean or median seizure frequency re-
duction of 24 to 31% over 3 months of follow-up in pa-
tients receiving the VNS treatment paradigm. Response
during the first 3 months of treatment is predictive of
long-term response18, which has also been shown in our
group of patients – we noticed significant mean seizure re-
duction in the first three months after VNS implantation.
According to the literature data, after 2 years of treat-
ment, patients achieve an overall average of 40 % reduc-
tion in seizure frequency. In 40 to 50 % of the patients,
the frequency of seizures can even be decreased by 50%.
Moreover, even in the absence of a significant reduction
of seizures, patients subjected to this treatment have re-
ported the improvement in their quality of life19. Other
authors report in their series decrease in mean seizure
frequency by 26% after 1 year, by 30% after 5 years, and
by 52% after 12 years with VNS treatment20. Results in
our series were even better – our MRI negative patients
experienced decrease in mean-seizure frequency of 51.67%
during 5 years and our MRI positive patients had better
results and experienced decrease in mean-seizure fre-
quency of 61.9 % during 2 years. Considering the fact
that, according to the literature, the best seizure reduc-
tion frequency is achieved after 5 years of VNS21, results
in our group of patients were even better, because the
significant decrease in mean seizure frequency was no-
ticed in the early follow-up period.
It is also important to emphasize that we had good re-
sults in decreasing seizure frequency with VNS in pa-
tients with primary generalized epilepsy, although the
primary indication of this mode of therapy is partial epi-
lepsy.
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TABLE 4
COMPARATION OF MONTHLY NUMBER OF SEIZURES BEFORE
AND AFTER VNS IMPLANTATION IN MRI POSITIVE PATIENTS
(FOLLOW UP: 2 YEARS)
Seizure type
Monthly number
of seizures before
implantation, X±SD
Monthly number
of seizures after
implantation, X±SD
EPS+CPS 16 8
EPS+CPS+SG
45±21.21
15±7.07 (only EPS);
p=0.2
CPS 16 8
CPS+SG
6.67±4.16
2±1.73 (only CPS);
p=0.1
CPS+SG+atonic 35±7.07
(serial seizures)
9.5±0.71 (only CPS);
p=0.03
Limitations of the study
We followed most of our MRI negative patients (11 of
them) during five years, but two of them were operated
recently and were followed only for one year. We de-
scribed the results of VNS efficacy in all 13 MRI negative
patients together, although there were not followed in
the same period of time, because we divided our patients
in two groups – MRI positive and MRI negative.
Intensity of the stimulation of VNS was not the same
in every patient, but this was dependent on the clinical
response and mean-seizure frequency in an individual
patient.
Conclusion
VNS was effective mode of therapy in our group of pa-
tients with pharmacoresistant epilepsy, including both
partial and generalized epilepsy. Decrease in mean sei-
zure frequency was achieved in the early follow-up pe-
riod and stayed stable in the later period. In all patients
in whom treatment with three medications in monothe-
rapy or combination therapy has failed, VNS may be con-
sidered as a viable option at this stage. VNS is associated
with a low rate of perioperative complications, and the
majority of side effects are stimulation-dependent and
thus reversible.
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STIMULACIJA VAGUSNOG @IVCA U LIJE^ENJU BOLESNIKA S FARMAKOREZISTENTNOM
EPILEPSIJOM: NA[A ISKUSTVA
S A @ E T A K
Stimulator vagusnog `ivca (engl. Vagus nerve stimulator – VNS) odobren je za lije~enje refraktornih parcijalnih
epilepti~kih ataka s ili bez sekundarne generalizacije u bolesnika starijih od 12 godina u Europi 1994. godine i u SAD-u
1997. godine. U na{em smo istra`ivanju pratili u~inkovitost VNS-a u bolesnika s farmakorezistentnom epilepsijom koji
su hospitalizirani u Klinici za neurologiju Klini~kog bolni~kog centra Zagreb. Od 1997. do 2001. godine VNS je ugra|en
u 11 bolesnika s farmakorezistentnom epilepsijom, koji su bili MR (magnetska rezonanca) negativni, a od svibnja 2007.
do svibnja 2009. godine u 11 bolesnika s farmakorezistentnom epilepsijom, od kojih je 9 bilo MR pozitivno, i nisu bili
kandidati za resektivno neurokirur{ko lije~enje zbog lokalizacije patomorfolo{kih promjena (gangliogliomi, hamartomi,
razli~iti tipovi kortikalne displazije, porencefali~ne ciste), a 2 bolesnika bilo je MR negativno. U grupi MR negativnih
bolesnika jedan bolesnik je imao kompleksne parcijalne epilepti~ke atake (engl. complex partial seizures - CPS), 6 bole-
snika imalo je CPS sa sekundarnom generalizacijom, 2 bolesnika imalo je primarno generaliziranu epilepsiju (PGE)
uklju~uju}i mioklone, absence, atoni~ke i toni~ko-kloni~ke epilepti~ke napadaje, jedan bolesnik imao je PGE i CPS, a 3
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bolesnika imalo je Lennox-Gastautov sindrom (LGS). U grupi MR pozitivnih bolesnika jedan bolesnik imao je ele-
mentarne parcijalne epilepti~ke atake (engl. elementary partial seizures - EPS) i CPS, dva bolesnika imala su EPS i
CPS sa sekundarnom generalizacijom, jedan bolesnik imao je CPS, 3 bolesnika imala su CPS sa sekundarnom gene-
ralizacijom, a 2 bolesnika imala su CPS sa sekundarnom generalizacijom kao i atoni~ke atake. Nakon kontinuiranog
pra}enja 11 MR negativnih bolesnika tijekom 5 godina te 2 MR negativna bolesnika tijekom godine dana na|eno je
smanjenje u prosje~noj u~estalosti epilepti~kih ataka za 51,67%. Nakon kontinuiranog pra}enja 9 MR pozitivnih bole-
snika tijekom 2 godine na|eno je smanjenje u prosje~noj u~estalosti epilepti~kih ataka za 61,9%. Naj~e{}e nuspojave
bile su promuklost, bol u grlu i ka{alj u »on-fazi« rada stimulatora. Navedene nuspojave bile su blagog intenziteta i
prolaznog karaktera. Stimulacija vagusnog `ivca pokazala se kao u~inkovit na~in lije~enja u na{oj grupi bolesnika s
farmakorezistentnom epilepsijom.
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